Pozelimab-bbfg (Veopoz)
Dilution requiredFull monograph review pending
U.S. label preparation
Veopoz · Dilution required
- Preparation
- For the IV loading dose, use a 25-250 mL bag of 0.9% sodium chloride or 5% dextrose to achieve 6.7-20 mg/mL.
- Administration and handling
- The maintenance doses are subcutaneous. Confirm the prescribed route and treatment stage before preparation.
Product and source details
Regeneron Pharmaceuticals, Inc. · BLA761339
Product NDC: 61755-014
SPL effective 2025-12-04 | SPL version 6. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.